+91
By proceeding, you agree to all T&C*
Didn't receive the code? Resend
MOREPENLAB

Morepen Laboratories Share Price

₹115.78 +0.5 (0.43%)
New 52W High in past week

11 Sep, 2026 3:59 PM (IST)

Morepen Laboratories live price: ₹115.78. It opened at ₹115 vs previous close ₹115; intraday high/low: ₹118/₹111. The 50 & 200 DMA stand at ₹86.10/₹60.70.

Morepen Laboratories Performance

  • Today's Low
  • ₹111
  • Today's High
  • ₹118
  • 52 Week Low
  • ₹33
  • 52 Week High
  • ₹123
  • Open Price₹115
  • Previous Close₹115
  • Volume16,276,533
  • 50 DMA₹86.10
  • 100 DMA₹71.30
  • 200 DMA₹60.70

Morepen Laboratories Chart

Investment Returns

  • Over 1 Month + 50.58%
  • Over 3 Month + 144.83%
  • Over 6 Month + 188.66%
  • Over 1 Year + 113.85%

Smart Investing Starts Here Start SIP with Morepen Laboratories for Steady Growth!

Invest Now

Morepen Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 45.1
  • PEG Ratio
  • 0.9
  • Market Cap Cr
  • 6,344
  • P/B Ratio
  • 4.9
  • Average True Range
  • 6.3
  • EPS
  • 2.6
  • Dividend Yield
  • 0
  • MACD Signal
  • 11.1
  • RSI
  • 72.16
  • MFI
  • 74.07

Latest Stock News Updates

Morepen Labs rises 7% to 52-week high; what moved this multibagger stock?

The gains in Morepen Labs come on the back of a positive business development announced by the company today involving the first phase of its manufacturing capacity expansion program.

Morepen Laboratories Ltd - 500288 - Announcement Under Regulation 30 Of The SEBI (LODR)

Business Update-First Phase of Manufacturing Capacity Expansion Completed Ahead of Schedule

Morepen Laboratories Ltd - 500288 - Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper publication for completion of dispatch of the notice of 41st AGM and Annual report for the FY 2025-26

Morepen Laboratories Financials

Morepen Laboratories Technicals

EMA & SMA

Current Price
₹115.78
+ 0.5 (0.43%)
pointer
  • Bearish Moving Average 1
  • Bullish Moving Average 15
  • 20 Day
  • ₹104.20
  • 50 Day
  • ₹86.10
  • 100 Day
  • ₹71.30
  • 200 Day
  • ₹60.70

Resistance and Support

114.83 Pivot Speed
  • R3 125.30
  • R2 121.50
  • R1 118.60
  • S1 112.00
  • S2 108.10
  • S3 105.30

Morepen Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-08-04 Quarterly Results
2026-05-26 Audited Results & Final Dividend (Revised)
2026-02-10 Quarterly Results
2025-11-14 Quarterly Results
2025-08-06 Quarterly Results & Others To consider other business matters.
Date Purpose Remarks
2026-09-19 FINAL Rs.0.20 per share(10%)Final Dividend
2025-08-30 FINAL Rs.0.20 per share(10%)Final Dividend
View Morepen Laboratories Dividend History Arrow
Date Purpose Remarks
2000-11-22 Split

Morepen Laboratories Shareholding Pattern

61.59%
35.65%
1.46%
1.29%

About Morepen Laboratories

Morepen Laboratories engaged with the medical fraternity and the wider public on matters of everyday health. Leveraging the leadership position of Saltum, the No. 1 brand in its category in the Indian pharmaceutical market, the Company conducted a dedicated campaign during Antimicrobial Resistance (AMR) Awareness Week to reinforce responsible antibiotic use among physicians and patients. View More
  • NSE Symbol
  • MOREPENLAB
  • BSE Symbol
  • 500288
  • ISIN
  • INE083A01026

Similar Stocks to Morepen Laboratories

Morepen Laboratories FAQs

Morepen Laboratories share price is ₹115 As on 12 September, 2026 | 23:07

The Market Cap of Morepen Laboratories is ₹6344.2 Cr As on 12 September, 2026 | 23:07

The P/E ratio of Morepen Laboratories is 45.1 As on 12 September, 2026 | 23:07

The PB ratio of Morepen Laboratories is 4.9 As on 12 September, 2026 | 23:07

The 52 week High & Low of Morepen Laboratories is ₹122.6/₹33 respectively As on 12 September, 2026 | 23:07

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23